Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial-Reference-Cited by-同舟云学术

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

Published:2009-02-19 Issue:7 Volume:23 Page:1337-1341
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Reeder C B,Reece D E,Kukreti V,Chen C,Trudel S,Hentz J,Noble B,Pirooz N A,Spong J E,Piza J G,Zepeda V H J,Mikhael J R,Leis J F,Bergsagel P L,Fonseca R,Stewart A K

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu200926.pdf

Reference33 articles.

1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy M, Hayman S, Buadi F et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.

2. Barlogie B, Tricot GJ, van Rhee F, Angtuaco E, Walker R, Epstein J et al. Long-term outcome results of the first tandem autotransplant trial for multiple myeloma. Br J Haematol 2006; 135: 158–164.

3. Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526.

4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer E, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487–2498.

5. Weber D . Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 2003; 10: 375–383.

Cited by 331 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. VCd vs VRd in Newly Diagnosed Multiple Myeloma: Matched Real-World Analysis from the Balkan Myeloma Study Group (BMSG);Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16;Blood Advances;2024-07-12

3. Multiple myeloma: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2024-06-28

4. Metronomic chemotherapy in hematology: Lessons from preclinical and clinical studies to build a solid rationale for future schedules;Cancer Letters;2024-06

5. Improved long-term survival rate in the responders to bortezomib, cyclophosphamide, dexamethasone induction therapy in a transplant-eligible cohort of predominantly middle-age multiple myeloma patients;Annals of Saudi Medicine;2024-03